JAZZ · Company research
Jazz Pharmaceuticals, Inc. (JAZZ): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
25records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy - Stocktwits | JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy Stocktwits | View source ↗ | Stocktwits | Oct 16, 2026 | neutral | 0 | 0.6 |
| Jazz Pharmaceuticals plc (JAZZ) Options Chain - Yahoo Finance - Yahoo! Finance Canada | Jazz Pharmaceuticals plc (JAZZ) Options Chain - Yahoo Finance Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| Is JAZZ Stock Still a Smart Way to Play Medical Cannabis? - Zacks Investment Research | Is JAZZ Stock Still a Smart Way to Play Medical Cannabis? Zacks Investment Research | View source ↗ | Zacks Investment Research | Oct 16, 2026 | neutral | 0 | 0.6 |
| Is JAZZ Stock Still a Smart Way to Play Medical Cannabis? - TradingView | Is JAZZ Stock Still a Smart Way to Play Medical Cannabis? TradingView | View source ↗ | TradingView | Oct 16, 2026 | neutral | 0 | 0.6 |
| HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? | Harmony Biosciences (HRMY) has outperformed the market with a 27.6% share surge over six months, driven by robust Wakix sales growth of 24% to $476.7 million in H1 2026 and promising pipeline candidates BP-205 and EPX-100. The company maintains its $1.0-$1.04B full-year revenue guidance and has $962.5M in cash to fund development. However, competition from Jazz Pharmaceuticals' Xywav and Alkermes' Lumryz, along with patent litigation risks, present headwinds. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.333 | 1 |
| HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? | Harmony Biosciences (HRMY) has outperformed the market with a 27.6% share surge over six months, driven by robust Wakix sales growth of 24% to $476.7 million in H1 2026 and promising pipeline candidates BP-205 and EPX-100. The company maintains its $1.0-$1.04B full-year revenue guidance and has $962.5M in cash to fund development. However, competition from Jazz Pharmaceuticals' Xywav and Alkermes' Lumryz, along with patent litigation risks, present headwinds. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.333 | 1 |
| Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings Story - Seeking Alpha | Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings Story Seeking Alpha | View source ↗ | Seeking Alpha | Oct 15, 2026 | neutral | 0 | 0.6 |
| What Jazz Pharmaceuticals Buyers Were Betting On - Simply Wall Street | What Jazz Pharmaceuticals Buyers Were Betting On Simply Wall Street | View source ↗ | Simply Wall Street | Oct 15, 2026 | neutral | 0 | 0.6 |
| Jazz Pharmaceuticals plc (JAZZ) Stock Forecasts - Yahoo Finance | Jazz Pharmaceuticals plc (JAZZ) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| Jazz Pharmaceuticals gets Cramer’s vote of confidence - TheStreet | Jazz Pharmaceuticals gets Cramer’s vote of confidence TheStreet | View source ↗ | TheStreet | Oct 14, 2026 | neutral | 0 | 0.6 |
| Jim Cramer Gives Green Light To This Health Care Stock - Benzinga | Jim Cramer Gives Green Light To This Health Care Stock Benzinga | View source ↗ | Benzinga | Oct 12, 2026 | neutral | 0 | 0.6 |
| Utah Jazz Stock Report: 3 Players I'm Buying and 3 I'm Selling So Far - Sports Illustrated | Utah Jazz Stock Report: 3 Players I'm Buying and 3 I'm Selling So Far Sports Illustrated | View source ↗ | Sports Illustrated | Oct 12, 2026 | neutral | 0 | 0.6 |
| Form 144 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY For: 11 October - Investing.com Nigeria | Form 144 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY For: 11 October Investing.com Nigeria | View source ↗ | Investing.com Nigeria | Oct 11, 2026 | neutral | 0 | 0.6 |
| Jazz Pharmaceuticals (JAZZ) Faces A Succession Test Following An Undervalued View - Simply Wall Street | Jazz Pharmaceuticals (JAZZ) Faces A Succession Test Following An Undervalued View Simply Wall Street | View source ↗ | Simply Wall Street | Oct 10, 2026 | neutral | 0 | 0.6 |
| Jazz Pharmaceuticals plc (JAZZ) Stock Forecasts - Yahoo! Finance Canada | Jazz Pharmaceuticals plc (JAZZ) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 10, 2026 | neutral | 0 | 0.6 |
| Cramer's lightning round: 'I'm going to say yes to Jazz Pharmaceuticals' - CNBC | Cramer's lightning round: 'I'm going to say yes to Jazz Pharmaceuticals' CNBC | View source ↗ | CNBC | Oct 9, 2026 | neutral | 0 | 0.6 |
| The commercial chief at Jazz Pharmaceuticals (JAZZ) plans to retire by June 30, 2027. - Stock Titan | The commercial chief at Jazz Pharmaceuticals (JAZZ) plans to retire by June 30, 2027. Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Jazz Pharmaceuticals (NASDAQ:JAZZ): An Undervalued Biopharma Value Stock - ChartMill | Jazz Pharmaceuticals (NASDAQ:JAZZ): An Undervalued Biopharma Value Stock ChartMill | View source ↗ | ChartMill | Oct 9, 2026 | neutral | 0 | 0.6 |
| Jazz Pharmaceuticals Drops 5.1% Amid Sector-Wide Selling - AlphaStreet | Jazz Pharmaceuticals Drops 5.1% Amid Sector-Wide Selling AlphaStreet | View source ↗ | AlphaStreet | Oct 8, 2026 | neutral | 0 | 0.6 |
| A director proposes selling Jazz Pharmaceuticals (JAZZ) shares after a $436K sale. - Stock Titan | A director proposes selling Jazz Pharmaceuticals (JAZZ) shares after a $436K sale. Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| Jazz Pharmaceuticals Falls as Traders Weigh Minor Target Cut and Recent Insider-Sale Filings - Quiver Quantitative | Jazz Pharmaceuticals Falls as Traders Weigh Minor Target Cut and Recent Insider-Sale Filings Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 8, 2026 | neutral | 0 | 0.6 |
| Jazz Pharmaceuticals plc (JAZZ) Stock Forecasts - Yahoo Finance | Jazz Pharmaceuticals plc (JAZZ) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 7, 2026 | neutral | 0 | 0.6 |
| Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock | Zacks Premium offers investment research tools including the Zacks Rank and Style Scores to help investors identify stocks with strong performance potential. The Zacks Rank #1 stocks have averaged +23.86% annual returns since 1988, more than double the S&P 500. Style Scores (Value, Growth, Momentum, and VGM) help narrow down top-rated stocks by evaluating their characteristics. Jazz Pharmaceuticals is highlighted as a stock to watch with a #3 Hold rank and VGM Score of A. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 1 | 1 |
| Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock | Zacks Premium offers investment research tools including the Zacks Rank and Style Scores to help investors identify stocks with strong performance potential. The Zacks Rank #1 stocks have averaged +23.86% annual returns since 1988, more than double the S&P 500. Style Scores (Value, Growth, Momentum, and VGM) help narrow down top-rated stocks by evaluating their characteristics. Jazz Pharmaceuticals is highlighted as a stock to watch with a #3 Hold rank and VGM Score of A. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 1 | 1 |
| Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases - PR Newswire | Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases PR Newswire | View source ↗ | PR Newswire | Aug 26, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.